Phase 1
Completed N=75
Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects
GERD
Source: ClinicalTrials.gov NCT05742984 ↗
Enrolled (actual)
75
Serious AEs
1.4%
Results posted
May 2025
Primary outcomePrimary: AUC0-24h Linaprazan (QD) — 5057; 8924; 13900; 4640 nmol/L*h
Summary
This is a Phase I, single-center, open label parallel-group, randomized study designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD, by continuous intragastric pH measurment), safety and tolerability of single and repeated oral doses of linaprazan glurate in 3 different dose levels given once- (QD) or twice daily (BID), for 14 days, with an additional single dose after 2, 4 or 6 days of drug holiday. The population will include healthy male and female subjects.
The subjects will be followed up to 28 days post IMP dosing.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY AUC0-24h Linaprazan (QD) |
5057; 8924; 13900; 4640; 8626; 11697 | — |
| PRIMARY AUC0-12, 12-24h Linaprazan (BID) |
4081; 8084; 11814; 3947; 7107; 9532 | — |
| PRIMARY Cmax Linaprazan (QD) |
527.5; 1066.23; 1594.42; 404.75; 1002.00; 1044.92 | — |
| PRIMARY Cmax Linaprazan (BID) |
658.42; 1380.18; 1942.00; 520.92; 997.09; 1283.90 | — |
| PRIMARY AUC0-24h Linaprazan Glurate (QD) |
42; 99; 166; 27; 107; 149 | — |
| PRIMARY AUC0-12h, 12-24h Linaprazan Glurate (BID) |
40; 117; 179; 30; 74; 78 | — |
| PRIMARY Cmax Linaprazan Glurate (QD) |
27.54; 62.24; 100.46; 18.43; 126.31; 107.07 | — |
| PRIMARY Cmax Linaprazan Glurate (BID) |
32.52; 101.26; 148.19; 14.69; 46.60; 40.41 | — |
| PRIMARY Percentage of Time Gastric pH >4 Over a 24-hour Monitoring Period (Holding Time Ratio, HTR) |
48; 64.6; 68.1; 76.0; 87.4; 94.5 | — |
Eligibility Criteria
Inclusion Criteria
- Willing and able to give written informed consent for participation in the study.
- Healthy male or female subject aged 18 to 65 years, inclusive.
- Body mass index ≥ 18.5 and ≤ 30.0 kg/m2.
- Medically healthy, without abnormal clinically significant medical history, physical findings, vital signs, ECGs, or laboratory values at the time of screening, as judged by the Investigator.
Exclusion Criteria
- Female subjects of childbearing potential (defined as all subjects physiologically capable of becoming pregnant)
- Male subjects with a partner of childbearing potential
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History of GERD or clinically significant acid reflux, as judged by the Investigator.
Data sourced from ClinicalTrials.gov (NCT05742984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.